Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that through its collaboration agreement with a...

Related Keywords

Texas ,United States ,Genentech Tecentriq ,Mark Berger ,Kalyn Dabbs ,Rodney Varner ,Exchange Commission ,Linkedin ,Drug Administration ,Genprex Inc ,Prnewswire Genprex Inc ,Facebook ,Company Website ,Expands Clinical Trial Sites ,Treat Small Cell Lung ,Fast Track ,Immunogene Therapy ,Chief Executive Officer ,Chief Medical Officer ,Maximum Tolerated Dose ,Recommended Phase ,Ophran Drug ,Delivery System ,Fast Track Designation ,Private Securities Litigation Reform Act ,Annual Report ,Nasdaq Capital Market ,